Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of underlying ...

AdHoc Studios has released the first patch for Dispatch for 2026, and this is a bigger-than-expected download — at least on consoles. Don’t expect any new content from this, as this is purely for bug ...

Toyota is tightening the focus of its motorsport efforts with a shake-up that includes a new hypercar and a fresh identity for its racing division. After spinning off Gazoo Racing (GR) as a standalone ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. There were no reports of serious adverse events with MCO ...

DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive long-term safety results from its EXTEND study, a five-year follow-up of participants who received a single ...

REMAIN results showed sustained, 3-line vision gains vs baseline through 152 weeks for MCO-010 in patients having severe vision loss from retinitis pigmentosa, and a favorable safety profile The data ...

Android Canary 2510 is available now for the Pixel 6 and newer hardware. Changes include a new UI for flashlight brightness control. Android’s been working on new options for three-button navigation, ...

A timeless silhouette with a cult following is getting a fresh, new look. Nike is set to release the Air Max Plus in a sleek “Black/Metallic Silver-Dark Grey” colorway, a design that takes the iconic ...

A first-in-class obesity drug, presented at the European Association for the Study of Diabetes meeting in Vienna, aims to reprogramme metabolism rather than suppress appetite – offering the potential ...

A first-in-class antisense oligonucleotide — RES-010 (Resalis Therapeutics, Turin, Italy) — may complement and enhance the efficacy of antiobesity drugs such as GLP-1 receptor agonists (RAs), ...